The Health Technology Podcast

Evan Anderson, CEO & Board Member, Luma Therapeutics Evan Anderson, CEO and Board Member of Luma Therapeutics, has 17 years of experience in early stage product and market development. He completed the Stanford Biodesign Fellowship in 2004 and was first manager of R&D and then distribution sales at Spiracur (acquired by Acelity). From the Luma Therapeutics website: We are a medical device company developing light therapies for the 40 million people in the US with inflammatory skin disorders. Luma Therapeutics was born when our CEO Evan Anderson found that he had psoriasis and discovered a way to treat himself effectively. He knew then that he wanted to develop similar treatments for the millions of other people suffering from skin disorders. We work hard every day to help people get clear skin with easy to use, affordable therapies. Our goal is to develop an at home treatment that will put psoriasis in remission for an extended period of time after only a few weeks of therapy.

Kirsten Carroll, Vice President, Strategic Development, Imperative Care Kirsten Carroll holds over 15 years of experience in product development, marketing, strategy and business development for medical devices in stroke care. In November 2017, she joined Imperative Care (an Incept Company), working under the leadership of Fred Khosravi. Prior to her new role, Kirsten was the Senior Director of Strategic Development at Stryker Neurovascular, leading business intelligence, NV services products and BD deal modeling and diligence activities. Kirsten’s first 8 years at Stryker Neurovascular (previously Boston Scientific) were spent in a succession of marketing management roles in the access and hemorrhagic stroke franchises. During that tenure she acted as marketing lead on multiple product development teams, the MAPS Trial, and ultimately the Target Coil, which went on to realize over $1B in revenue to-date and remains the #1 embolization coil in the world. Following the neurovascular division’s acquisition by Stryker in 2011, Kirsten moved into Marketing Operations, ultimately building it into a 9-person Strategic Development function that managed business development, portfolio planning and business intelligence. She holds 2 patents on pre-shaped microcatheters and is a contributing author on 3 publications in the American Journal of Neuroradiology. Kirsten earned a B.Sc. in biomedical engineering from Yale University and an MBA and MPH from the Haas School of Business at UC Berkeley.

Michael Seres, Founder & CEO, 11 Health Michael Seres, the Founder/ CEO of 11 Health and Technologies Limited, was diagnosed with the incurable bowel condition, Crohn's Disease at the age of 12. After over 20 operations and an intestinal failure, Michael became the 11th person to undergo a small bowel transplant at the Churchill Hospital in Oxford, UK, which included becoming a stoma patient. Additionally, Michael is also a 2-time Cancer patient. In 2013, Michael founded the health tech start up 11 health and has developed sensor technology for ostomy patients. Michael, started blogging about his journey through Bowel Transplant and his blog now has over 100,000 followers. He uses social media to develop global online peer to peer communities: covering over 20,000 patients. He is now the patient lead for the main UK health twitter chat #NHSSM, a member of the NHS England Digital Services user council, a published author and a professional speaker. He is the inaugural e-patient in residence and an executive board member at Stanford Medicine X. Michael helped implement the first skype clinics in Oxford Hospital and is an ambassador to the Doctors 2.0 conference.

Derek Herrera, Founder & CTO, Spinal Singularity Former Marine Special Operations Officer now working to create change as an entrepreneur in the medical device Industry. Passionate about utilizing advanced technology to create meaningful products to improve people's lives. An ethical, hard-working leader with proven performance in building successful teams able to accomplish the most challenging of missions in austere, kinetic environments. Demonstrated capacity in building teams across multiple functional areas. Excels at strategic planning, problem framing, and identifying innovative solutions.

Adam Schoen, Partner, Brown Rudnick Adam Schoen advises life science and medical device companies regarding implementation of a patent strategy to further business objectives and business goals. Adam’s practice encompasses patent preparation and prosecution, portfolio development, product clearance, freedom to operate analysis and intellectual property due diligence. Adam works with public and private companies, investors, and academic institutions. Adam has experience with a variety of technologies, such as next generation sequencing technologies, droplet based technologies, cancer diagnostics, medical device technology (ophthalmology, cardiology, orthopedics, neurology, spine) and medical imaging technology (IVUS and OCT), mass spectrometry, small molecule therapeutics, digital health, near field communication technology, and semiconductor technology. He manages patent portfolios of all sizes and develops strategies to maximize and protect intellectual property rights in both the United States and foreign jurisdictions. Prior to law school, Adam was a scientist of analytical chemistry for ArQule Inc., a combinatorial chemistry and drug discovery company.